Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as
neoadjuvant therapy for HER2-positive breast cancer.
Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer
(stage II-III, tumor size > 2 cm), with no estrogen (ER) and progesterone (PR) receptors will
be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.